New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:14 EDTVTR, Z, NPSP, PBYI, OMER, HCT, BRCM, CYTK, PCYC, PL, SHPG, MTZ, ARIAOn The Fly: Pre-market Movers
HIGHER: NPS Pharmaceuticals (NPSP), up 21% after the Times of London reported that Shire (SHPG) secured a $5B credit facility led by Citigroup (C) for a takeover offer for the company... Broadcom (BRCM), up 15% after saying it will explore strategic alternatives for cellular baseband business, backing Q2 revenue expectations... Protective Life (PL) rises 17% after Dai-ichi Life Insurance reported to be in talks to buy the company... American Realty Capital (HCT) up 10% after Ventas (VTR) agreed to acquire the company for $2.6B in stock and cash. Ventas shares down 1.8% in pre-market trade following the deal announcement... Conn's (CONN), up 10% after reporting better than expected Q1 earnings results... ARIAD (ARIA), up 13.5% after FDA lifts partial clinical hold on Iclusig study. LOWER: MasTec (MTZ), down 13% after lowering its Q2 EPS view... Puma Biotechnology (PBYI), down 16% after presentation of PB272 Phase II data... Cytokinetics falls 8.8% after announcing further results from BENEFIT-ALS trial... Zillow (Z), down 4% after shares downgraded at Pacific Crest and at RBC Capital.
News For NPSP;SHPG;BRCM;Z;PL;HCT;VTR;PCYC;OMER;ARIA;CYTK;PBYI;MTZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 24, 2015
09:22 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:37 EDTARIAARIAD announces approval of Iclusig in Israel
ARIAD Pharmaceuticals and Medison Pharma announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig, ponatinib, in Israel for adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation Philadelphia chromosome-positive acute lymphoblastic leukaemia who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation. ARIAD submitted its application for Iclusig to the Israeli Ministry of Health in June 2014. Commercial launch of Iclusig is expected to occur in Q2.
07:21 EDTBRCMBroadcom pause in set-top box orders is temporary, says Macquarie
Subscribe for More Information
March 23, 2015
09:45 EDTSHPGUBS to hold a field trip
Subscribe for More Information
09:37 EDTSHPGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
07:36 EDTSHPGPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 20, 2015
10:00 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:41 EDTSHPGBernstein global specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information
08:12 EDTSHPGShire upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Shire as the firm thinks that the stock's risk/reward ratio is positive following several new developments. Among these developments are the firm's belief that the company's orphan drug strategy looks increasingly strong, while the risks to the company's Vyvanse and mesalamines drugs look to have moderated and the company has several near-term, 2015 catalysts. Target $295.
07:24 EDTBRCMBroadcom chip renews competition with in-house hardware makers, WSJ says
Subscribe for More Information
March 18, 2015
08:03 EDTSHPGTherapeuticsMD names Angus Russell, J. Martin Carroll as directors
TherapeuticsMD (TXMD) announced the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors. Angus C. Russell served as CEO of Shire PLC (SHPG) from June 2008 until April 2013. J. Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. U.S. from 2003 until 2011.
07:22 EDTSHPGShire looking for 'transformational' deal, Betaville blog says
Subscribe for More Information
March 17, 2015
18:19 EDTMTZMasTec announces delay in filing FY14 Form 10-K
Subscribe for More Information
March 16, 2015
16:23 EDTOMEROmeros sees FY15 OpEx $110M-$120M
For 2015, the company anticipates that operating expenses will be in the $110M-$120M range with non-cash expenses of approximately $15M. This guidance is largely based on the continued preparations for the full-scale U.S. launch of Omidria as well as the continued development of the company's product pipeline.
16:22 EDTOMEROmeros reports Q4 EPS (61c) with items, consensus (62c)
Subscribe for More Information
15:31 EDTPCYCPharmacyclics resumes, up 0.6% to $256.58 after HELIOS hits primary endpoint
Subscribe for More Information
15:08 EDTPCYCPharmacyclics to resume trading at 3:30 pm EDT
Subscribe for More Information
15:04 EDTPCYCPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information
14:55 EDTPCYCPharmacyclics trading halted, pending news
07:40 EDTZZillow Group impact minimal from ListHub, says Canaccord
Canaccord believes Zillow will see little disruption from ListHub not sending its listings after the company won its legal battle against Trulia. News Corp. (NWSA) owned ListHub will stop sending the listings in April, but Canaccord believes the combined Zillow/Trulia guidance may hold some positive surprises and expects 2016 to be a breakout year for the company. Canaccord reiterated its Buy rating and $125 price target on Zillow shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use